Holen Sie sich die Stockscreener-App
2.65
3.11%
0.08
Handel nachbörslich:
2.79
0.14
+5.28%
Intelligent Bio Solutions Inc Aktie (INBS) Neueste Nachrichten
INBS Q1 2025 Earnings: EPS Misses Estimates as Company Reports No RevenueExpert Trade Signals - Newser
Intelligent Bio Solutions Inc. (INBS) Q1 2025 Earnings: Wider Loss Than Expected Weighs on SharesInstitutional Grade Picks - Newser
Intelligent Bio Solutions Inc. (INBS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Intelligent Bio Solutions Inc. (INBS) Q1 2025 Earnings: Wider-Than-Expected Loss Amid Continued Pre-Revenue StageTrending Entry Points - Newser
INBS|Intelligent Bio Solutions Inc|Price:2.530|Chg%:-0.10 - TradingKey
Intelligent Bio Solutions Company Profile & Introduction - Moomoo
Intelligent Bio Solutions 3Q Loss $2.87M >INBS - Moomoo
INBS - Finviz
[SCHEDULE 13G] INTELLIGENT BIO SOLUTIONS INC. Passive Investment Disclosure (>5%) - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Is Intelligent Bio Solutions (INBS) Undervalued After Q3 FY2026 - GuruFocus
Intelligent Bio Solutions (NASDAQ: INBS) grows Q3 revenue 46% with margins above 50% - Stock Titan
Intelligent Bio Reports Q3 Revenue Up 46%, Gross Margin Over 50% as Cartridge Sales Surge - TradingView
Intelligent Bio Solutions 3Q Loss/Shr $1.80 >INBS - Moomoo
Intelligent Bio Solutions Releases Q3 2026 Financial Results - AlphaStreet
Intelligent Bio Solutions Inc. Q3 2026 10-Q Filing: Financial Statements, Reverse Stock Split, and Company Overview - Minichart
Intelligent Bio Solutions Reports 46% Revenue Growth in Q3 FY202 - GuruFocus
Finger-scan drug test maker tops 50% margins as sales jump 46% - Stock Titan
Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50% - TradingView
INTELLIGENT BIO SOLUTIONS INC. 3Q 2026: Revenue $1.06M, Net loss $(2.86M) — 10-Q Summary - TradingView
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year - marketscreener.com
Intelligent Bio Solutions (NASDAQ: INBS) boosts revenue but warns on going concern - Stock Titan
Intelligent Bio Solutions Inc. Reports Unaudited Impairment of Long-Lived Assets for the Third Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
INBS Q3'26 Earnings: EPS estimate is 1.40 USD - TradingView
INBS Stock Price, Quote & Chart | INTELLIGENT BIO SOLUTIONS IN (NASDAQ:INBS) - ChartMill
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Intelligent Bio Solutions Inc (STU:12Q0) Stock Price & 30 Year Financial Data - GuruFocus
How Intelligent (INBS) is reshaping its industry (Trend Weakens) 2026-05-08Gap Down Stocks - newser.com
The moat Intelligent (INBS) is building for long term dominance (Breakdown Watch) 2026-05-05Top Breakouts - newser.com
Intelligent Bio Solutions expects 16% year over year growth in fourth quarter revenue - MSN
Is Intelligent (INBS) stock near resistance (-4.79%) 2026-04-22Verified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai
Intelligent Bio Solutions Updates Investor Presentation and Share Count - The Globe and Mail
Intelligent Bio : Investor DeckApril 2026 - marketscreener.com
Intelligent Bio Solutions (INBS) Launches Study to Enhance Drug Screening Speed - GuruFocus
Intelligent Bio Solutions Inc. Launches Validation Study to Achieve Sub-3-Minute Results in Roadside Drug Testing Technology - Quiver Quantitative
Fingerprint drug test aims for under-3-minute roadside results - Stock Titan
Intelligent Bio Solutions (NASDAQ: INBS) posts new investor deck and share update - Stock Titan
Is Intelligent (INBS) stock undervalued compared to peers (Extends Gains) 2026-04-20Theta Decay - Cổng thông tin điện tử tỉnh Lào Cai
INBS completes penetration testing for FDA 510(k) submission By Investing.com - Investing.com India
Intelligent Bio Solutions (INBS) Enhances Security Ahead of FDA Submission - GuruFocus
Intelligent Bio Solutions Inc. Advances Fda 510(K) Submission And Completes Penetration Testing - marketscreener.com
INBS completes penetration testing for FDA 510(k) submission - Investing.com
Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified - The Manila Times
No major security flaws found as Intelligent Bio readies FDA filing - Stock Titan
Is Intelligent (INBS) Stock Slowing Down | Price at $2.56, Up 4.07%Market Timing - Newser
How cyclical is Intelligent Bio Solutions Incs revenue stream2026 Price Swings & Smart Money Movement Tracker - baoquankhu1.vn
1.27%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):